"George has been a leader on campus for well over a decade when it comes to combining basic science advances with new technology development and translating that into molecules and treatments that address current medical needs," said Brent Iverson, the Warren J. and Viola Mae Raymer Professor and chairman of the Department of Chemistry and Biochemistry in the College of Natural Sciences. "Almost as important as his research contributions, Dr. Georgiou has inspired a remarkable number of this country's next generation of scientists. His former research group members are now starting their own independent research careers at many of the most elite research universities in the country and indeed, around the world."
Last year, Georgiou was awarded two grants from the newly formed Cancer Prevention and Research Institute of Texas. He was awarded $2.2 million to continue preclinical development of highly promising new proteins he developed for treating liver cancer, which has a median survival rate of only eight months. The grants also went toward his research on increasing the effectiveness of antibodies in cancer treatment.
"I am very pleased and honored by my election to the Institute of Medicine," Georgiou said. "In turn, I wish to thank my amazing research team and my collaborators for helping bring our cancer drug candidates to the clinic. I look forward to the new transformative medical discovery technologies we are developing."
Georgiou holds joint appointments in the Department of Chemical Engineering, the Department of Biomedical Engineering and the College of Natural Sciences' Department of Molecular Genetics and Microbiology.
He is co-inventor of more than 45 U.S. patents and patent applications that have been licensed to 16 biotechnology or pharmaceutical companies. In addition to the National Academy of Engineering, Georgiou is a member of th
|Contact: Melissa Mixon|
University of Texas at Austin